Alzheimer’s Therapeutics Market

• June 2025: INmune Bio reported Phase II results from its MINDFuL trial evaluating XPro™ in early Alzheimer’s disease with inflammatory biomarkers.
• June 2025: Eli Lilly announced FDA approval of a label update for Amyvid, an imaging agent used to assess amyloid plaque density.
• April 2025: Biogen received FDA Fast Track designation for BIIB080, an antisense therapy targeting tau pathology.
• February 2025: Annovis Bio initiated patient enrollment in its pivotal Phase III trial of Buntanetap for early-stage Alzheimer’s disease.
  
  

Alzheimer’s Disease Overview

Alzheimer’s disease is a progressive neurodegenerative condition characterized by cognitive decline, memory impairment, and behavioral changes. It is the leading cause of dementia in older adults and is associated with hallmark pathological features such as beta-amyloid plaques and neurofibrillary tangles. Diagnosis relies on clinical evaluation, cognitive testing, imaging, and, in some cases, biomarker analysis.

Alzheimer’s Disease Epidemiology Segmentation

The epidemiology analysis covers the 7MM from 2020 to 2034 and includes segmentation by diagnosed prevalent cases, preclinical cases, age, gender, disease severity, genotype, agitation, and psychosis associated with Alzheimer’s disease.

Alzheimer’s Disease Market Report Metrics

• Study Period: 2020–2034
• Geographic Coverage: 7MM (US, EU4, UK, Japan)
• Market Size (2024): USD 5 Billion
• Key Companies: Novo Nordisk, Eli Lilly, Biogen, Eisai, Johnson & Johnson, TauRx Therapeutics, and others
• Key Therapies: Masitinib, Valiltramiprosate, Buntanetap, Bezisterim, Semaglutide, Remternetug, LEQEMBI, KISUNLA, and others

Scope of the Alzheimer’s Disease Market Report

• Comprehensive therapeutic assessment of marketed and emerging treatments
• Market dynamics, forecast assumptions, and outlook
• Competitive intelligence, SWOT analysis, and market entry strategies
• Evaluation of unmet needs, KOL perspectives, and reimbursement landscape